Install
Your go-to source for the latest news in health, science and medicine. Sign up for STAT+ for exclusive analysis of biotech, pharma, and the life sciences.
- 203articles · 30d
- 14+ hour agolatest article
- Aug 16, 2026earliest in window
- 95%with images
- 246avg words
- Medical 150
- Health & Wellness 138
- Health 100
- Science & Technology 46
- Business & Industrial 37
- Economy, Business & Finance 22
- Politics 19
- Politics2 18
Please confirm you are human
This browser or connection looks automated. Press and continuously hold the control for 3 seconds to enable Google-hosted web results and, when separately allowed, AI-assisted answers.
A successful check enables 100 search requests. Interactive access does not authorize scraping, systematic collection, or reuse of search output.
News
One of the most consequential year for cancer treatment, ever
3+ week, 4+ day ago (191+ words) Adam Feuerstein is a senior writer and biotech columnist for STAT, reporting on the crossroads of drug...also a cohost of STAT's weekly "The Readout LOUD" podcast and the author of the weekly newsletter Adam's...In 2022, a series of stories…...
Capricor Therapeutics' Duchenne treatment is heading for an FDA rejection
3+ week, 4+ day ago (190+ words) Adam Feuerstein is a senior writer and biotech columnist for STAT, reporting on the crossroads of drug...also a cohost of STAT's weekly "The Readout LOUD" podcast and the author of the weekly newsletter Adam's...In 2022, a series of stories…...
Eyepoint study results for vision treatment disappoint, but company still sees promise
3+ week, 6+ day ago (247+ words) Adam Feuerstein is a senior writer and biotech columnist for STAT, reporting on the crossroads of drug...also a cohost of STAT's weekly "The Readout LOUD" podcast and the author of the weekly newsletter Adam's...In 2022, a series of stories…...
What to expect from UniQure's upcoming Huntington's gene therapy readout
4+ day, 1+ hour ago (242+ words) Adam Feuerstein is a senior writer and biotech columnist for STAT, reporting on the crossroads of drug...also a cohost of STAT's weekly "The Readout LOUD" podcast and the author of the weekly newsletter Adam's...In 2022, a series of stories…...
Roivant lung disease drug hits mid-stage study goals
6+ day, 2+ hour ago (242+ words) Adam Feuerstein is a senior writer and biotech columnist for STAT, reporting on the crossroads of drug...also a cohost of STAT's weekly "The Readout LOUD" podcast and the author of the weekly newsletter Adam's...In 2022, a series of stories…...
Why two promising heart drugs flopped and what's next
3+ day, 19+ hour ago (222+ words) By Adam Feuerstein, Elaine Chen, and Allison DeAngelis On this week’s episode of “The Readout LOUD”:...By Allison DeAngelis and Elaine Chen By Elaine Chen, Adam Feuerstein, and Allison DeAngelis By Allison...DeAngelis, Elaine Chen, and Adam Feuerstein...
FDA approves Protagonist and Takeda’s drug for rare blood cancer
2+ week, 18+ hour ago (105+ words) By Matthew Herper, Jason Mast, and Angus Chen By Adam Feuerstein and Angus Chen...
In autopsy of failed heart disease study, AstraZeneca raises broader questions about silencer drugs
2+ week, 3+ day ago (138+ words) By Matthew Herper, Jason Mast, and Angus Chen By Adam Feuerstein and Angus Chen...
Vaccines take center stage at federal autism advisory committee
2+ week, 3+ day ago (137+ words) Debra Houry, Daniel Jernigan, and Demetre Daskalakis By Matthew Herper, Jason Mast, and Angus Chen By Adam...Feuerstein and Angus Chen...
GLP-1 drugs are almost single-handedly forcing employers to reconsider workers' health care
1+ week, 6+ day ago (146+ words) By Matthew Herper, Jason Mast, and Angus Chen By Adam Feuerstein and Angus Chen...